Catecholamine treatment for shock--equally good or bad?
Singer
Mervyn
M
Bloomsbury Institute of Intensive Care Medicine, Wolfson Institute for Biomedical Research and Department of Medicine, University College London, London WC1E 6BT, UK. m.singer@ucl.ac.uk
D000322:Adrenergic Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004280:Dobutamine / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009638:Norepinephrine / Q000008:administration & dosage* / Q000009:adverse effects; D012772:Shock, Septic / Q000188:drug therapy*
D000322:Adrenergic Agonists; D004280:Dobutamine; D009638:Norepinephrine; D004837:Epinephrine